Group 1 - Sanofi announced the acquisition of Vigil Neuroscience for $470 million in cash, with the total price potentially rising to $600 million upon achieving certain development milestones [1] - The acquisition price of $8 per share represents a 236% premium over Vigil's closing price prior to the announcement, and shareholders may receive an additional $2 per share if Vigil's Alzheimer's treatment drug VG-3927 achieves commercial sales within a specified timeframe [1] - This acquisition focuses on the neurology field, which is one of Sanofi's four core strategic disease areas, and aims to strengthen its early-stage research pipeline in neurodegenerative diseases [1] Group 2 - The global aging trend has created significant unmet medical needs in the treatment of neurodegenerative diseases like Alzheimer's, prompting Sanofi to adopt a dual strategy of "in-house development + targeted acquisitions" to build a differentiated central nervous system drug pipeline [2]

Core Viewpoint - Sanofi has entered into a definitive merger agreement to acquire Vigil Neuroscience for an upfront payment of $8.00 per share, with potential additional payments based on the commercial success of VG-3927, valuing the total equity of the transaction at approximately $600 million on a fully diluted basis [1][5][6]. Company Overview - Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring the function of microglia, the immune cells of the brain [11]. - The company is developing VG-3927, a small molecule TREM2 agonist aimed at treating Alzheimer's disease, and has a pipeline that includes therapies for both rare and common neurodegenerative diseases [11]. Transaction Details - The merger agreement stipulates that Vigil's shareholders will receive $8.00 per share in cash at closing, plus a contingent value right (CVR) that could yield an additional $2.00 per share upon the first commercial sale of VG-3927 [1][5][6]. - The acquisition is expected to close in the third quarter of 2025, subject to customary conditions including shareholder approval and regulatory clearances [8]. Strategic Rationale - Sanofi's acquisition of Vigil aligns with its strategic focus on neurology and the development of innovative therapies for critical unmet needs in neurodegenerative diseases [4]. - The TREM2 target is seen as a promising area for addressing immune dysregulation and neurodegeneration, particularly in Alzheimer's patients who currently have limited treatment options [4][2]. Development Potential - The acquisition is anticipated to strengthen the development path for VG-3927, which is positioned as a Phase 2-ready clinical candidate for Alzheimer's disease [5][6]. - Activating TREM2 is expected to enhance the neuroprotective function of microglia, potentially preventing neural degeneration associated with adult-onset neurodegenerative diseases [2][3].

Company Overview - Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by restoring the function of microglia, the immune cells of the brain [11] - The company is developing VG-3927, a novel small molecule TREM2 agonist aimed at treating Alzheimer's disease [11] Acquisition Details - Sanofi has entered into a definitive merger agreement to acquire Vigil for an upfront payment of $8.00 per share in cash, with a potential additional $2.00 per share contingent value right (CVR) based on the first commercial sale of VG-3927 [2][6] - The total equity value of the transaction, including the potential CVR payment, is approximately $600 million on a fully diluted basis [2] - The acquisition is expected to close in the third quarter of 2025, subject to customary conditions including shareholder approval [8] Strategic Implications - The acquisition is expected to strengthen Sanofi's development capabilities in neurology, particularly in advancing therapies for Alzheimer's disease [5][3] - Activating TREM2 is anticipated to enhance the neuroprotective function of microglia, addressing the dysregulation seen in neurodegenerative diseases [3] - There is a critical need for more effective and safer treatment options for Alzheimer's disease, as current therapies do not stop or reverse disease progression [4] Financial Aspects - Vigil shareholders will receive a total of up to $10.00 per share, consisting of $8.00 at closing and a potential $2.00 CVR [1][2] - The equity value of the transaction represents approximately $470 million based on the upfront cash payment [6] Additional Information - Iluzanebart, Vigil's monoclonal antibody program, will not be part of the acquisition and will return to Amgen prior to the transaction closing [7] - The transaction is supported by voting and support agreements representing approximately 16% of Vigil's total common shares outstanding [7]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________________ to ___________________ Commission File Number 001-41200 VIGIL NEUROSCIENCE, INC. (Exact name of Registrant as specified in its Charter) De ...

Exhibit 99.1 Vigil Neuroscience Reports First Quarter 2025 Financial Results and Provides Recent Business Updates – On track to report final analysis from IGNITE Phase 2 clinical trial evaluating iluzanebart in ALSP in Q2 2025 – - Plans to initiate Phase 2 clinical trial evaluating VG-3927 in Alzheimer's disease in Q3 2025 – WATERTOWN, Mass., May. 7, 2025 — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neur ...

Core Insights - Vigil Neuroscience is advancing its clinical programs, with key milestones expected in 2025, including the final analysis of iluzanebart in ALSP and the initiation of a Phase 2 trial for VG-3927 in Alzheimer's disease [1][2][3] Clinical Development Updates - The final analysis from the IGNITE Phase 2 clinical trial for iluzanebart is scheduled for Q2 2025, with plans for an accelerated approval pathway in ALSP [3] - VG-3927 has shown positive Phase 1 data, supporting the initiation of a Phase 2 trial in Q3 2025 for Alzheimer's disease [2][4] - The Phase 1 trial for VG-3927 included 115 participants, demonstrating a favorable safety profile and significant pharmacokinetic and pharmacodynamic results [4] Financial Performance - As of March 31, 2025, the company reported cash, cash equivalents, and marketable securities of $87.1 million, down from $97.8 million at the end of 2024, with expectations to fund operations into 2026 [9][13] - Research and Development (R&D) expenses for Q1 2025 were $16.5 million, an increase from $14.3 million in Q1 2024, driven by higher costs in preclinical and manufacturing activities [9][11] - The net loss for Q1 2025 was $22.4 million, compared to $19.9 million for the same period in 2024, with a net loss per share of $0.49 [9][11]

Core Insights - Vigil Neuroscience presented topline clinical data from the Phase 1 SAD/MAD trial of VG-3927, a potential treatment for Alzheimer's disease, at the AD/PD™ 2025 International Conference [1][2] Group 1: VG-3927 Overview - VG-3927 is an orally bioavailable small molecule TREM2 agonist with high potency and CNS penetrance, designed to target multiple contributors to Alzheimer's disease progression [2][8] - The drug's unique mechanism as both an agonist and a positive allosteric modulator may enhance microglial responses to aggregated amyloid and tau without increasing inflammation [8] Group 2: Phase 1 Trial Results - The Phase 1 trial included 115 participants, demonstrating a favorable safety and tolerability profile with no serious adverse events reported [5][7] - VG-3927 showed a predictable and dose-dependent pharmacokinetic profile, supporting once-daily dosing with an estimated cerebral spinal fluid to unbound plasma ratio of 0.91 [5][11] Group 3: Mechanism of Action - VG-3927 activates TREM2, engaging the brain's immune system to counteract multiple pathologies associated with Alzheimer's disease [3][4] - The drug promotes microglial uptake of both Aβ and Tau, indicating broad efficacy potential beyond targeting a single driver of Alzheimer's pathology [4][6] Group 4: Future Development Plans - Vigil Neuroscience plans to advance VG-3927 into Phase 2 development in the third quarter of 2025, aiming to provide a differentiated therapeutic option for Alzheimer's disease [2][6]

Vigil Neuroscience, Inc. (VIGL) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.The power o ...

Financial Performance - The company incurred a net loss of $84.3 million for the year ended December 31, 2024, with an accumulated deficit of $307.0 million as of the same date[215]. - The company expects to continue incurring significant losses for the foreseeable future, with anticipated increases in losses as development and commercialization efforts continue[215]. - The company believes its existing cash, cash equivalents, and marketable securities will fund operations into 2026, but there is substantial doubt about its ability to continue as a going concern[220]. - The company has not generated any product revenue since its inception and does not have any products approved for sale[215]. - The company currently generates no revenue from product sales and may never be able to commercialize a marketable product[241]. Development and Regulatory Challenges - The company has not yet completed any late-stage clinical trials or obtained regulatory approvals for its therapeutic candidates[214]. - The company faces significant risks and uncertainties associated with biopharmaceutical product development, making future success difficult to predict[216]. - The company’s operating results may fluctuate significantly due to various factors, including regulatory approvals and market acceptance of its therapeutic candidates[226]. - The company may face significant delays or inability to successfully commercialize therapeutic candidates if it does not meet regulatory requirements or complete necessary studies[244]. - The company is highly dependent on the success of ongoing and future clinical trials of its lead clinical candidate, iluzanebart, and any issues could significantly harm its business[245]. Financing and Capital Requirements - The company will require additional financing to achieve its goals, and failure to obtain necessary capital could delay or terminate development programs[220]. - The company has sold 8,671,793 shares of common stock under its ATM program, generating aggregate net proceeds of $22.8 million as of March 11, 2025, with approximately $76.5 million remaining available for issuance[235]. - The company has filed a Registration Statement for the registration of common stock, preferred stock, debt securities, warrants, and units, with an aggregate amount of $100.0 million under the 2023 Shelf[235]. - The company may need to turn to other funding sources if it cannot raise additional equity capital through its ATM program, which could adversely affect its operations[236]. Clinical Trials and Product Development - The lead clinical candidate, iluzanebart, is currently being studied in a Phase 2 clinical trial for adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP)[239]. - VG-3927, a novel small molecule TREM2 agonist, is being developed for the treatment of common neurodegenerative diseases, with completed data from a Phase 1 clinical trial for Alzheimer's disease reported in January 2025[240]. - Clinical trials are expensive and can take many years to complete, with outcomes being inherently uncertain, potentially leading to delays in regulatory approvals[254]. - The company may encounter substantial delays in clinical trial enrollment and completion due to challenges in identifying eligible patients, particularly for rare diseases[258]. - The company’s product development costs will increase if there are delays in clinical testing or marketing approvals, potentially impairing its ability to commercialize therapeutic candidates[264]. Intellectual Property Risks - The company faces risks related to intellectual property disputes that could impair its ability to commercialize therapeutic candidates[300]. - The company relies on third-party licensors for important patent and intellectual property rights, which could impact the development of therapeutic programs[327]. - The patent prosecution process is expensive and complex, and the company may not be able to maintain or enforce all necessary patents[322]. - The company may face challenges in protecting its intellectual property rights globally, leading to potential vulnerabilities in certain jurisdictions[334]. - The validity and enforceability of the company's patents covering therapeutic candidates may be challenged, leading to potential narrowing or invalidation of patent rights, which could materially impact its business[337]. Regulatory Compliance and Legal Risks - The company must comply with regulatory requirements for clinical trials, and failure to do so could result in significant delays and penalties[304]. - The company is subject to the EU General Data Protection Regulation (GDPR), which imposes strict requirements on the handling of personal data and could result in substantial fines for non-compliance[368]. - The company faces intense competition for qualified personnel in the Boston area, which may hinder its ability to attract and retain skilled employees necessary for growth[411]. - Compliance with evolving privacy and data security laws could increase costs and expose the company to significant fines or penalties[363]. - The company may face claims challenging the inventorship or ownership of its intellectual property rights, which could result in litigation and loss of valuable rights if unsuccessful[346]. Market and Competitive Landscape - The commercial success of therapeutic candidates depends on market acceptance by physicians, patients, and healthcare payors, which is influenced by factors such as clinical efficacy, pricing, and reimbursement availability[394][396]. - Future healthcare reforms may result in more rigorous coverage criteria and downward pressure on product pricing, impacting revenue generation and profitability[401]. - The ability to commercialize therapeutic candidates is contingent on adequate coverage and reimbursement from government and private payors, which is critical for new product acceptance[399][400]. - The company faces significant liabilities from clinical trial and product liability lawsuits, which could divert resources and limit commercialization efforts[281]. Employee and Management Risks - The company faces challenges in retaining key personnel, which could adversely affect business and product development[412]. - The employment of key employees is at-will, allowing them to leave with or without notice[412]. - The company has implemented stock options that vest over time to retain valuable employees, which may be affected by stock price movements[412]. - In May 2024, the board of directors approved a stock option repricing to provide added incentives for key contributors[412].

Clinical Trials - Positive Phase 1 data for VG-3927 indicates a robust and dose-dependent reduction of sTREM2 by up to approximately 50% in the cerebral spinal fluid, supporting its advancement to Phase 2 trial[6] - The final analysis from the IGNITE Phase 2 clinical trial for iluzanebart is planned for the second quarter of 2025, with an intention to pursue an accelerated approval pathway[3] - The company plans to initiate the Phase 2 trial for VG-3927 in Q3 2025, marking it as the first and only Phase 2-ready oral small molecule TREM2 agonist[2] - The Phase 1 trial for VG-3927 included 115 participants, with 89 receiving the drug, demonstrating a favorable safety and tolerability profile[6] - The company expects to present Phase 1 data at the AD/PD™ 2025 International Conference on Alzheimer's and Parkinson's Disease in April 2025[6] Financial Performance - Cash, cash equivalents, and marketable securities were $97.8 million as of December 31, 2024, down from $111.3 million as of September 30, 2024, expected to fund operations into 2026[6] - Research and Development (R&D) expenses increased to $62.3 million for the year ended December 31, 2024, compared to $60.9 million in 2023, driven by increased clinical activity[6] - General and Administrative (G&A) expenses decreased to $27.4 million for the year ended December 31, 2024, from $27.9 million in 2023, attributed to lower external professional service fees[6] - Net loss for the fourth quarter was $23.8 million, compared to $22.2 million for the same period in 2023, with a total net loss of $84.3 million for the year ended December 31, 2024[6] - Total assets decreased to $117.7 million as of December 31, 2024, from $140.9 million in 2023, while total liabilities increased to $46.1 million from $24.6 million[13]